ReviewCurrent cardiology reports2026
Epigenetic Control of Mammalian Cardiomyocyte Proliferation.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPostnatal shutdown of the mammalian cardiomyocyte cell cycle underpins limited regenerative capacity of the adult heart. An epigenetic programme regulates a switch at birth from a proliferative state to functional maturity. Identification of the molecular components regulating this switch has revealed therapeutic opportunities for heart regeneration that have started entering the clinic. RECENT
findingsGenome-wide analyses reveal that histone modifications and DNA methylation remodel chromatin in adult cardiomyocytes, downregulating cell cycle activation genes while upregulating maturation genes. Epigenetic regulation of upstream transcriptional pathways (e.g. YAP, WNT and Notch) prevents cell cycle activation in the adult heart. Upregulating glycolysis or suppressing oxidative metabolism enhances cardiac repair following injury, with hypoxia demonstrating safety in humans. Gene therapy techniques enabling myocardial targeting have enhanced the translation of cardiac regenerative therapies, with YAP upregulation paving the way for future trials. The cardiomyocyte cell cycle is regulated by CDKs/cyclins controlled by transcriptional networks that are epigenetically suppressed in the postnatal period. Adult cardiomyocytes also harbour structural barriers and a metabolic state preventing proliferation. Pharmacological and genetic manipulation of these mechanisms can re-activate adult cardiomyocyte proliferation. However, regenerative therapies are challenged by the intrinsic link between proliferation and epigenetics, metabolism, and ultimately cardiac function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.